Autologous hematopoietic stem cell transplant at experienced centers in the current era can include indefinite disease ...

FDA clearance allows Imviva to test CTA313, an off-the-shelf CAR T-cell therapy, in progressive MS and other autoimmune ...

A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows ...

Using the approved multiple sclerosis therapy Kesimpta helps keep relapsing MS stable over time for most adults, a real-world ...

Key Takeaways An already-approved MS drug can help people with the progressive form of the diseaseOcrelizumab delayed ...

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

A cross-section of the spinal cord showing neurons and glial cells. (Juan Carlos Juarez Jaramillo/iStock/Getty Images Plus) A ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...